419 related articles for article (PubMed ID: 20013580)
1. The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention.
Joy S; Rhea DJ; Istwan NB; Desch CN; Stanziano G
Am J Perinatol; 2010 Apr; 27(4):343-8. PubMed ID: 20013580
[TBL] [Abstract][Full Text] [Related]
2. Women receiving 17-alpha-hydroxyprogesterone caproate hospitalized for preterm labor at less than 34 weeks benefit from daily perinatal nursing surveillance.
Rittenberg C; Sullivan S; Istwan N; Rhea D; Stanziano G; Newman R
Am J Obstet Gynecol; 2008 Oct; 199(4):389.e1-4. PubMed ID: 18928983
[TBL] [Abstract][Full Text] [Related]
3. Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery.
Rebarber A; Istwan NB; Russo-Stieglitz K; Cleary-Goldman J; Rhea DJ; Stanziano GJ; Saltzman DH
Diabetes Care; 2007 Sep; 30(9):2277-80. PubMed ID: 17563346
[TBL] [Abstract][Full Text] [Related]
4. The use of 17 alpha-hydroxyprogesterone caproate (17p) in women with cervical cerclage.
Rebarber A; Cleary-Goldman J; Istwan NB; Rhea DJ; Desch C; Russo-Stieglitz K; Saltzman DH
Am J Perinatol; 2008 May; 25(5):271-5. PubMed ID: 18401840
[TBL] [Abstract][Full Text] [Related]
5. 17 hydroxyprogesterone for the prevention of preterm delivery.
Meis PJ;
Obstet Gynecol; 2005 May; 105(5 Pt 1):1128-35. PubMed ID: 15863556
[TBL] [Abstract][Full Text] [Related]
6. Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery.
Gonzalez-Quintero VH; Cordova YC; Istwan NB; Tudela F; Rhea DJ; Romary LM; Marimon A; Desch CN; Stanziano GJ
Am J Obstet Gynecol; 2011 Sep; 205(3):275.e1-5. PubMed ID: 22071063
[TBL] [Abstract][Full Text] [Related]
7. Preterm birth prevention by 17 alpha-hydroxyprogesterone caproate vs. daily nursing surveillance.
Rittenberg C; Newman RB; Istwan NB; Rhea DJ; Stanziano GJ
J Reprod Med; 2009 Feb; 54(2):47-52. PubMed ID: 19301566
[TBL] [Abstract][Full Text] [Related]
8. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States.
Petrini JR; Callaghan WM; Klebanoff M; Green NS; Lackritz EM; Howse JL; Schwarz RH; Damus K
Obstet Gynecol; 2005 Feb; 105(2):267-72. PubMed ID: 15684150
[TBL] [Abstract][Full Text] [Related]
9. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery.
González-Quintero VH; Istwan NB; Rhea DJ; Smarkusky L; Hoffman MC; Stanziano GJ
J Matern Fetal Neonatal Med; 2007 Mar; 20(3):249-52. PubMed ID: 17437227
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?
How HY; Barton JR; Istwan NB; Rhea DJ; Stanziano GJ
Am J Obstet Gynecol; 2007 Sep; 197(3):260.e1-4. PubMed ID: 17826411
[TBL] [Abstract][Full Text] [Related]
11. The impact of acute tocolysis on neonatal outcome in women hospitalized with preterm labor at 32 to 34 weeks' gestation.
Elliott JP; Istwan NB; Rhea DJ; Desch CN; Stanziano GJ
Am J Perinatol; 2009 Feb; 26(2):123-8. PubMed ID: 18850519
[TBL] [Abstract][Full Text] [Related]
12. Recurrent preterm birth in women treated with 17 α-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy.
Coleman S; Wallace L; Alexander J; Istwan N
J Matern Fetal Neonatal Med; 2012 Jul; 25(7):1034-8. PubMed ID: 21854134
[TBL] [Abstract][Full Text] [Related]
13. Impact of prior gestational age at preterm delivery on effectiveness of 17-alpha-hydroxyprogesterone caproate in practice.
González-Quintero VH; de la Torre L; Rhea DJ; Tudela CM; Vazquez-Vera E; Desch C; Istwan NB
Am J Obstet Gynecol; 2010 Sep; 203(3):257.e1-5. PubMed ID: 20678745
[TBL] [Abstract][Full Text] [Related]
14. The effects of a preterm labor episode prior to 34 weeks are evident in late preterm outcomes, despite the administration of betamethasone.
Bastek JA; Sammel MD; Rebele EC; Srinivas SK; Elovitz MA
Am J Obstet Gynecol; 2010 Aug; 203(2):140.e1-7. PubMed ID: 20522406
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics of women prescribed 17 alpha-hydroxyprogesterone caproate in the community setting.
Rittenberg C; Sullivan S; Istwan N; Rhea D; Stanziano G; Newman R
Am J Obstet Gynecol; 2007 Sep; 197(3):262.e1-4. PubMed ID: 17826412
[TBL] [Abstract][Full Text] [Related]
16. The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate.
Ventolini G; Duke J; Po W; Barhan S; Rhea D; Desch C; Istwan N; Stanziano G
J Reprod Med; 2008 Sep; 53(9):667-71. PubMed ID: 18839818
[TBL] [Abstract][Full Text] [Related]
17. Management of recurrent preterm labor in twin gestations with nifedipine tocolysis.
de la Torre L; Istwan NB; Desch C; Rhea DJ; Roca L; Stanziano GJ; González-Quintero VH
Am J Perinatol; 2008 Oct; 25(9):555-60. PubMed ID: 18773381
[TBL] [Abstract][Full Text] [Related]
18. Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogesterone caproate.
Rebarber A; Ferrara LA; Hanley ML; Istwan NB; Rhea DJ; Stanziano GJ; Saltzman DH
Am J Obstet Gynecol; 2007 Mar; 196(3):224.e1-4. PubMed ID: 17346529
[TBL] [Abstract][Full Text] [Related]
19. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery.
Spong CY; Meis PJ; Thom EA; Sibai B; Dombrowski MP; Moawad AH; Hauth JC; Iams JD; Varner MW; Caritis SN; O'Sullivan MJ; Miodovnik M; Leveno KJ; Conway D; Wapner RJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S;
Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 2):1127-31. PubMed ID: 16157124
[TBL] [Abstract][Full Text] [Related]
20. Twins and preterm labor.
Rust OA; Perry KG; Andrew ME; Roberts WE; Martin RW; Morrison JC
J Reprod Med; 1997 Apr; 42(4):229-34. PubMed ID: 9131496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
